Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Rating) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 2,030,000 shares, a growth of 5.7% from the February 13th total of 1,920,000 shares. Based on an average daily trading volume, of 276,400 shares, the days-to-cover ratio is currently 7.3 days.
Wall Street Analysts Forecast Growth
Separately, Wedbush upgraded Aquestive Therapeutics from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $3.00 to $4.00 in a report on Thursday, March 9th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Aquestive Therapeutics has a consensus rating of “Buy” and a consensus target price of $8.30.
Institutional Investors Weigh In On Aquestive Therapeutics
Large investors have recently bought and sold shares of the stock. Beacon Pointe Advisors LLC acquired a new position in shares of Aquestive Therapeutics during the second quarter worth about $38,000. Mackenzie Financial Corp purchased a new position in Aquestive Therapeutics in the second quarter worth approximately $39,000. Virtu Financial LLC grew its holdings in Aquestive Therapeutics by 893.1% during the 2nd quarter. Virtu Financial LLC now owns 106,408 shares of the company’s stock worth $68,000 after acquiring an additional 95,693 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Aquestive Therapeutics by 204.7% in the 1st quarter. Renaissance Technologies LLC now owns 34,300 shares of the company’s stock valued at $90,000 after purchasing an additional 23,043 shares during the last quarter. Finally, BNP Paribas Arbitrage SA raised its holdings in shares of Aquestive Therapeutics by 118.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 34,810 shares of the company’s stock valued at $91,000 after purchasing an additional 18,860 shares in the last quarter. Hedge funds and other institutional investors own 29.35% of the company’s stock.
Aquestive Therapeutics Stock Down 4.0 %
Aquestive Therapeutics (NASDAQ:AQST – Get Rating) last posted its quarterly earnings data on Wednesday, March 8th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.02). The firm had revenue of $10.68 million during the quarter, compared to analyst estimates of $9.93 million. During the same quarter in the prior year, the company earned ($0.38) earnings per share. Research analysts forecast that Aquestive Therapeutics will post -0.78 earnings per share for the current year.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.
- Get a free copy of the StockNews.com research report on Aquestive Therapeutics (AQST)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.